Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase Ⅲ Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)

NCT03457311 is registered in ClinicalTrials.gov with Richever Enterprise Co., Ltd. as lead sponsor.

NCT NCT03457311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03457311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase Ⅲ Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)
Lead sponsor
Richever Enterprise Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
September 9, 2013
Completion date
March 31, 2018
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

galactose single point (gsp), residual liver function